Clinical Cancer Research Prevention Award AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katayama, A.
Right arrow Articles by Harabuchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katayama, A.
Right arrow Articles by Harabuchi, Y.
Clinical Cancer Research Vol. 10, 634-640, January 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and Prognosis

Akihiro Katayama, Nobuyuki Bandoh, Kan Kishibe, Miki Takahara, Takeshi Ogino, Satoshi Nonaka and Yasuaki Harabuchi

Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical College, Asahikawa, Japan

Purpose: Matrix metalloproteinase (MMP)-2 and MMP-9 are considered to play an important role in the metastasis of malignant tumors. Membrane type 1-MMP (MT1-MMP) and tissue inhibitor of metalloproteinase 2 (TIMP-2) are essential factors for the activation of pro-MMP-2. There are some reports about expressions of MMP family in relationship to clinical features of head and neck squamous cell carcinoma (SCC), but the results were not uniform and the prognostic value of their expressions remains unclear.

Experimental Design: The study group consisted of 53 Japanese patients with oral SCC of early stage (T1-2N0M0). Expressions of MMP-2, MMP-9, MT1-MMP, and TIMP-2 were examined using immunohistological methods on the sections of tumor biopsy samples. The intensity of MMP expression was categorized into four grades (score 0–3) by semiquantitative analysis using a computer with NIH image, and correlation between this grade and clinical aspects such as tumor recurrence, metastasis, and prognosis were examined.

Results: The expression score of MMP-2 correlated with that of MMP-9 (r = 0.291; P = 0.036), MT1-MMP (r = 0.286; P = 0.039), and TIMP-2 (r = 0.257; P = 0.050). Patients who developed regional lymph node and/or distant metastasis showed significantly higher scores in the expressions of MMP-9 and TIMP-2 than patients without any tumor metastases (P = 0.036 and P = 0.043, respectively). Kaplan-Meier analyses as well as univariate analyses using the Cox proportional hazards model showed that expression of MMP-9 (P = 0.0143 and P = 0.0418, respectively) and marked expression of TIMP-2 (P < 0.0001 and P = 0.0004, respectively) correlated with worse-cause-specific survival. Multivariate analysis confirmed that marked expression of TIMP-2 was the only independent factor for cause-specific death (hazard ratio, 7.543; confidence interval, 1.693–33.610; P = 0.0080).

Conclusions: Expressions of MMP-9 and TIMP-2 have predictive value for tumor metastases and cause-specific survival. High expression of TIMP-2 is the most independent factor for worse prognosis in early-stage oral SCC.




This article has been cited by other articles:


Home page
NEJMHome page
R. I. Haddad and D. M. Shin
Recent Advances in Head and Neck Cancer
N. Engl. J. Med., September 11, 2008; 359(11): 1143 - 1154.
[Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
I. M. G. Agra, A. L. Carvalho, C. A. L. Pinto, E. P. Martins, J. G. Filho, F. A. Soares, and L. P. Kowalski
Biological Markers and Prognosis in Recurrent Oral Cancer After Salvage Surgery
Arch Otolaryngol Head Neck Surg, July 1, 2008; 134(7): 743 - 749.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. S. Mitra, M. Goto, J. S. Lee, D. Maldonado, J. M.G. Taylor, Q. Pan, T. E. Carey, C. R. Bradford, M. E. Prince, K. G. Cordell, et al.
Rap1GAP Promotes Invasion via Induction of Matrix Metalloproteinase 9 Secretion, Which Is Associated with Poor Survival in Low N-Stage Squamous Cell Carcinoma
Cancer Res., May 15, 2008; 68(10): 3959 - 3969.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
S. Choi and J.N. Myers
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Journal of Dental Research, January 1, 2008; 87(1): 14 - 32.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. R. Basile, K. Holmbeck, T. H. Bugge, and J. S. Gutkind
MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D
J. Biol. Chem., March 2, 2007; 282(9): 6899 - 6905.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
J. Verstappen and J.W. Von den Hoff
Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease
Journal of Dental Research, December 1, 2006; 85(12): 1074 - 1084.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. G. Remacle, A. V. Chekanov, V. S. Golubkov, A. Y. Savinov, D. V. Rozanov, and A. Y. Strongin
O-Glycosylation Regulates Autolysis of Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP)
J. Biol. Chem., June 23, 2006; 281(25): 16897 - 16905.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. G. Remacle, D. V. Rozanov, P. C. Baciu, A. V. Chekanov, V. S. Golubkov, and A. Y. Strongin
The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP)
J. Cell Sci., November 1, 2005; 118(21): 4975 - 4984.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Arora, J. Kaur, C. Sharma, M. Mathur, S. Bahadur, N. K. Shukla, S. V.S. Deo, and R. Ralhan
Stromelysin 3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous and Cancerous Lesions: Correlation with Microvessel Density, Progression, and Prognosis
Clin. Cancer Res., March 15, 2005; 11(6): 2272 - 2284.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. R. Spitz, X. Wu, and G. Mills
Integrative Epidemiology: From Risk Assessment to Outcome Prediction
J. Clin. Oncol., January 10, 2005; 23(2): 267 - 275.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma
Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis
Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. C. K. Jordan, M. Macabeo-Ong, C. H. Shiboski, N. Dekker, D. G. Ginzinger, D. T. W. Wong, and B. L. Schmidt
Overexpression of Matrix Metalloproteinase-1 and -9 mRNA Is Associated with Progression of Oral Dysplasia to Cancer
Clin. Cancer Res., October 1, 2004; 10(19): 6460 - 6465.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.